Home › Funds › Casdin Capital › BLFS

Casdin Capital position in BLFS

BIOLIFE SOLUTIONS INC · Health Care

Casdin Capital reported holding 4,500,000 shares of BLFS (BIOLIFE SOLUTIONS INC) in its Q3 2026 13F filing — a position valued at US$174.8M, representing 7.64% of its reported portfolio and ranking #4 among its reported holdings. Casdin Capital has disclosed BLFS holdings in 34 of the last 34 reported quarters, going back to Q2 2018.

Latest position (Q3 2026)4.50M sh
Reported value held$174.82M
Portfolio Weight7.64%
First reportedQ2 2018
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Casdin Capital's BLFS position evolved

Casdin Capital first disclosed a stake in BLFS in Q2 2018 at 1,000,000 shares (US$11.4M). The position peaked in Q3 2019 at 2,428,571 shares, worth US$40.37B. Across 34 filings, Casdin Capital increased the stake 9 time(s), trimmed it 5 time(s) and left it unchanged 19 time(s). The most recent filing (Q3 2026) shows 4,500,000 shares valued at US$174.8M — a reduction of -155,000 shares quarter over quarter.. Notable position changes include a 143% increase in Q3 2018, a 96% increase in Q2 2020, a 27% increase in Q4 2020.

Quarter by quarter

QuarterSharesValueChange
Q2 2018 1.00M $11.41M New
Q3 2018 2.43M $42.50M Add
Q4 2018 2.43M $29.22M Hold
Q1 2019 2.43M $43.45M Hold
Q2 2019 2.43M $39.41B Hold
Q3 2019 2.43M $40.37B Hold
Q4 2019 2.47M $39.94M Add
Q1 2020 2.47M $23.45M Hold
Q2 2020 4.85M $79.29M Add
Q3 2020 5.84M $169.01M Add
Q4 2020 7.44M $296.79M Add
Q1 2021 7.44M $267.84M Hold
Q2 2021 7.44M $331.16M Hold
Q3 2021 7.57M $320.20M Add
Q4 2021 7.57M $282.00M Hold
Q1 2022 7.57M $171.98M Hold
Q2 2022 7.57M $104.49M Hold
Q3 2022 7.57M $172.13M Hold
Q4 2022 7.57M $137.74M Hold
Q1 2023 7.57M $164.68M Hold
Q2 2023 7.72M $170.65M Add
Q3 2023 7.78M $107.44M Add
Q4 2023 8.71M $141.49M Add
Q1 2024 8.71M $161.52M Hold
Q2 2024 8.71M $186.59M Hold
Q3 2024 8.71M $218.03M Hold
Q4 2024 8.71M $226.04M Hold
Q1 2025 8.71M $198.87M Hold
Q2 2025 7.71M $166.01M Reduce
Q3 2025 6.71M $171.10M Reduce
Q4 2025 5.96M $144.04M Reduce
Q1 2026 5.96M $113.66M Hold
Q2 2026 4.66M $131.46M Reduce
Q3 2026 4.50M $174.82M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BLFS and 13F data

BLFS (BIOLIFE SOLUTIONS INC) is a Health Care company. 38 other funds we track also report a position in BLFS — the largest reported positions include First Trust Capital Management L.P. (US$55.4M), AQR Arbitrage LLC (US$43.8M), Magnetar Financial LLC (US$42.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BLFS

All BLFS fund holders →

FAQ

How long has Casdin Capital held BLFS?

Casdin Capital has disclosed BLFS holdings in 34 of the last 34 reported quarters, going back to Q2 2018.

What is Casdin Capital's current position in BLFS?

As of Q3 2026, Casdin Capital holds 4.50M shares of BLFS (BIOLIFE SOLUTIONS INC), valued at $174.82M, representing 7.64% of its reported portfolio and ranking #4.

Has Casdin Capital been buying or selling BLFS?

In the latest 13F filing (Q3 2026), Casdin Capital reduced its position in BLFS. The position peaked in Q3 2019 at 2.43M shares.

Which other funds hold BLFS?

Other major institutional holders of BLFS include First Trust Capital Management L.P., AQR Arbitrage LLC, Magnetar Financial LLC, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.